Sacubitril/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure.

CONCLUSIONS: The present experience showed that angiotensin receptor-neprilysin inhibitor (ARNi) might represent a new valuable therapeutic strategy, even at the earlier stages of stabilized acute HF. Therefore, we suggest a clinical practice algorithm, to consider before discharge, which should be validated by further analyses. PMID: 30864896 [PubMed - in process]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research